MaaT Pharma Logo

MaaT Pharma

A clinical-stage biotech developing microbiome-based therapeutics for oncology.

MAAT | PA

Overview

Corporate Details

ISIN(s):
FR0012634822 (+1 more)
LEI:
969500CQQB6XUNW6CN97
Country:
France
Address:
70 AVENUE TONY GARNIER, 69007 LYON

Description

MaaT Pharma is a clinical-stage biotechnology company specializing in the development of microbiome-based therapeutics. The company's primary focus is on oncology, aiming to improve survival outcomes for cancer patients by modulating the immune system through the gut microbiome. It develops Microbiome Ecosystem Therapies (MET) designed to restore gut microbiome symbiosis. The company's pipeline includes product candidates for treating complications in patients with blood cancers and solid tumors, with its lead candidate, MaaT013, in late-stage development for acute Graft-versus-Host Disease (aGvHD). MaaT Pharma utilizes an AI-powered platform for drug development and has its own cGMP manufacturing capabilities.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-12-15 10:41
Franchissement de seuils
French 108.0 KB
2025-12-08 18:00
Inside Information / Other news releases
English 139.6 KB
2025-12-08 18:00
Informations privilégiées / Autres communiqués
French 145.6 KB
2025-11-21 11:22
Franchissement de seuils
French 107.2 KB
2025-11-14 23:05
Inside Information / Operations of the issuer (acquisitions, sales...)
English 121.9 KB
2025-11-14 23:05
Informations privilégiées / Opérations de l'émetteur (acquisitions, cessions...)
French 176.1 KB
2025-11-13 19:40
Inside Information / Other news releases
English 193.4 KB
2025-11-13 19:40
Informations privilégiées / Autres communiqués
French 156.5 KB
2025-11-05 07:30
Inside Information / Other news releases
English 162.7 KB
2025-11-05 07:30
Informations privilégiées / Autres communiqués
French 132.6 KB
2025-11-04 07:30
Inside Information / News release on accounts, results
English 109.1 KB
2025-11-04 07:30
Informations privilégiées / Communiqué sur comptes, résultats
French 167.6 KB
2025-11-03 18:00
Inside Information / Other news releases
English 150.3 KB
2025-11-03 18:00
Informations privilégiées / Autres communiqués
French 163.0 KB
2025-10-13 14:47
Franchissement de seuils
French 106.3 KB

Automate Your Workflow. Get a real-time feed of all MaaT Pharma filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for MaaT Pharma

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for MaaT Pharma via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2024-07-12 N/A Other Sell 8 60.87 EUR
2024-07-11 N/A Other Sell 57 436.14 EUR
2023-12-22 N/A Other Buy 2,940 14,994.00 EUR
2023-12-22 N/A Other Buy 1,960 9,996.00 EUR
2023-09-27 N/A Other Buy 500 3,050.00 EUR

Peer Companies

Vor Biopharma Inc. Logo
A clinical-stage biotech developing therapies that target the source of autoimmunity.
United States of America
VOR
WDB coco CO.,LTD. Logo
A CRO providing support services to the pharmaceutical and medical device sectors.
Japan
7079
Whitehawk Therapeutics, Inc. Logo
A preclinical oncology company developing advanced antibody-drug conjugate therapies.
United States of America
WHWK
WOOJUNG BIO, Inc. Logo
Offers pre-clinical CRO services, research facility engineering, and startup incubation.
South Korea
215380
XEROS TECHNOLOGY GROUP PLC Logo
Develops and licenses polymer-based solutions that reduce industrial water consumption.
United Kingdom
XSG
Xilio Therapeutics, Inc. Logo
A clinical-stage biotech developing tumor-activated immuno-oncology therapies for cancer.
United States of America
XLO
Xintela AB Logo
Biomedical company developing stem cell therapies for regenerative medicine and oncology.
Sweden
XINT
Xlife Sciences AG Logo
Develops and commercializes early-stage life sciences research projects.
Switzerland
XLS
Y-Biologics, Inc Logo
Develops antibody-based therapeutics for cancer, focusing on immuno-oncology.
South Korea
338840
YD Bio Ltd Logo
Develops blood-based cancer diagnostics and regenerative cell therapies.
United States of America
YDES

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.